Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.40 |
| ▸ | TXNRD3 | Q86VQ6 | 2/20 | 0.40 |
| ▸ | TXNRD2 | Q9NNW7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11316994 | 0.71 | ALDH1A1 (0.41) | ALDH1A1KAT2BMEN1KMT2AMAPT | |
| SCHEMBL29517954 | 0.71 | TXNRD1 (0.51) | ALDH1A1TXNRD1TXNRD3TXNRD2MAPT | |
| SCHEMBL1011755 | 0.71 | TXNRD1 (0.51) | ALDH1A1TXNRD1TXNRD3TXNRD2MAPT | |
| SCHEMBL15300582 | 0.71 | ALDH1A1 (0.45) | ALDH1A1KAT2BTXNRD1TXNRD3TXNRD2 | |
| SCHEMBL3587546 | 0.71 | SMN1; SMN2 (0.53) | ALDH1A1KAT2BMEN1KMT2AMAPT | |
| SCHEMBL15879743 | 0.70 | ALDH1A1 (0.51) | ALDH1A1KAT2BMEN1KMT2AMAPT | |
| SCHEMBL31106335 | 0.70 | TXNRD1 (0.50) | ALDH1A1TXNRD1TXNRD3TXNRD2MAPT | |
| SCHEMBL6782564 | 0.69 | NQO2 (0.45) | ALDH1A1TXNRD1TXNRD3TXNRD2MEN1 | |
| SCHEMBL6781909 | 0.69 | ALDH1A1 (0.48) | ALDH1A1TXNRD1TXNRD3TXNRD2MEN1 | |
| SCHEMBL6782693 | 0.69 | ALDH1A1 (0.45) | ALDH1A1TXNRD1TXNRD3TXNRD2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | ALDH1A1 1265/4885KAT2B 1761/4885TXNRD1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.